Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral, Small-Molecule Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor AZD6244 (ARRY-142886) in Patients With Advanced Cancers

PURPOSE: To assess the tolerability, pharmacokinetics (PKs), and pharmacodynamics (PDs) of the mitogen-activated protein kinase kinase (MEK) 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancer. PATIENTS AND METHODS: In part A, patients received escalating doses to determine the maxi...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Adjei, Alex A., Cohen, Roger B., Franklin, Wilbur, Morris, Clive, Wilson, David, Molina, Julian R., Hanson, Lorelei J., Gore, Lia, Chow, Laura, Leong, Stephen, Maloney, Lara, Gordon, Gilad, Simmons, Heidi, Marlow, Allison, Litwiler, Kevin, Brown, Suzy, Poch, Gregory, Kane, Katie, Haney, Jerry, Eckhardt, S. Gail
Format: Artigo
Idioma:Inglês
Publicat: 2008
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2718422/
https://ncbi.nlm.nih.gov/pubmed/18390968
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2007.14.4956
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars